Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug makes intubation safer? major trial tests remifentanil vs rocuronium

NCT ID NCT06564857

Knowledge-focused Sponsor: Nordsjaellands Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial compares two drugs—remifentanil (a strong painkiller) and rocuronium (a muscle relaxant)—for placing a breathing tube during surgery using a video laryngoscope. About 2,648 adults undergoing general anesthesia will be randomly assigned to one drug. The goal is to see which causes fewer complications like low oxygen, heart issues, or failed first attempts at tube placement. The results could help make intubation safer for millions of patients worldwide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remifentanil and rocuronium
What this could lead to
If it works, this could show that using remifentanil instead of rocuronium for intubation is safer and reduces complications like breathing problems or awareness during surgery.
What could go wrong
This is a large phase 4 trial, but it compares two drugs already in use, so it won't lead to a new treatment. The results may only apply to video laryngoscopy and not change standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 2,648 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥ 18 years * Undergoing general anaesthesia requiring oro-tracheal intubation * Absence of indication for rapid sequence induction * American Society of Anesthesiologists (ASA) physical status score I - III Exclusion Criteria: * Known allergies or contraindications to rocuronium (e.g. neuromuscular disease) or remifentanil * Awake intubation * Double-lumen endotracheal tube * Oral, pharyngeal, and laryngeal surgery * Surgical contraindication for NMBAs (e.g. use of nerve stimulator) * Patients who are pregnant or breastfeeding * Patients who do not understand Danish or are unable to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Remifentanil are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Remifentanil Rocuronium Tracheal intubation Video laryngoscopy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Anesthesiology, NOH, Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

  • Department of Anesthesiology, North Zeeland Hospital

    RECRUITING

    Hillerød, 3400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.